Back

Verastem Oncology publishes two-year RAMP 201 data in ovarian cancer

Verifying
  • Verastem Oncology announced publication of RAMP 201 follow-up data in Gynecologic Oncology.
  • Two-year median follow-up data covered AVMAPKI FAKZYNJA CO-PACK in ovarian cancer.
  • RAMP 201 studied the treatment in recurrent low-grade serous ovarian cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Verastem Oncology publishes two-year RAMP 201 data in ovarian cancer - CoinPost Terminal